Development of cross-protective influenza A vaccines based on cellular responses

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Soema, Peter Christiaan ^a,b   Van Riet, Elly ^a   Kersten, Gideon ^a,b   Amorij, Jean Pierre ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Correlates of protection; Cross reactive immune response; Influenza A virus; Influenza vaccines; Peptide vaccines; T cell vaccines

Indexed keywords

ACID PROTEIN; CHEMOKINE RECEPTOR CCR5; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INFLUENZA VACCINE; NUCLEAR MATRIX PROTEIN 1; NUCLEAR MATRIX PROTEIN 2; NUCLEAR PROTEIN; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIROSOME; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; DRUG FORMULATION; HLA SYSTEM; HOST CELL; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MARKET; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VIRAL CLEARANCE;

EID: 84930942863     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00237     Document Type: Review

References (87)

1. Van Riet E, Ainai A, Suzuki T, Hasegawa H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine (2012) 30:5893-900. doi: 10.1016/j.vaccine.2012.04.109
2. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, et al. M2e-based universal influenza A vaccine. Vaccine (2009) 27:6280-3. doi:10.1016/j.vaccine.2009.07.007
3. Jang YH, Seong BL. Options and obstacles for designing a universal influenza vaccine. Viruses (2014) 6:3159-80. doi:10.3390/v6083159
4. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 333:843-50. doi:10.1126/science.1204839
5. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 333:850-6. doi:10.1126/science.1205669
6. Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A (2014) 111:E2514-23. doi:10.1073/pnas.1402766111
7. Kedzierska K, Valkenburg SA, Doherty PC, Davenport MP, Venturi V. Use it or lose it: establishment and persistence of T cell memory. Front Immunol (2012) 3:357. doi:10.3389/fimmu.2012.00357
8. Brown LE, Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol (2009) 87:300-8. doi:10.1038/icb.2009.16
9. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med (2009) 15:277-84. doi:10.1038/nm.1929
10. Bot A, Bot S, Bona CA. Protective role of gamma interferon during the recall response to influenza virus. J Virol (1998) 72:6637-45.
11. Seo SH, Webster RG. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol (2002) 76:1071-6. doi:10.1128/JVI.76.3.1071-1076.2002
12. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med (2013) 19:1305-12. doi:10.1038/nm.3350
13. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol (2010) 84:6527-35. doi:10.1128/jvi.00519-10
14. Hillaire ML, Vogelzang-Van Trierum SE, Kreijtz JH, De Mutsert G, Fouchier RA, Osterhaus AD, et al. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol (2013) 94:583-92. doi:10.1099/vir.0.048652-0
15. Van De Sandt CE, Kreijtz JH, De Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-Van Trierum SE, et al. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol (2014) 88:1684-93. doi:10.1128/jvi.02843-13
16. Hillaire ML, Van Trierum SE, Bodewes R, Van Baalen CA, Van Binnendijk RS, Koopmans MP, et al. Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol (2011) 85:12057-61. doi:10.1128/jvi.05204-11
17. Van De Sandt CE, Hillaire ML, Geelhoed-Mieras MM, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. Human influenza A virus-specific CD8+ T cell response is long-lived. J Infect Dis (2015). doi:10.1093/infdis/jiv018
18. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 393:478-80. doi:10.1038/30996
19. Alam S, Knowlden ZA, Sangster MY, Sant AJ. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol (2014) 88:314-24. doi:10.1128/jvi.02077-13
20. Olson MR, Seah SG, Cullen J, Greyer M, Edenborough K, Doherty PC, et al. Helping themselves: optimal virus-specific CD4 T cell responses require help via CD4 T cell licensing of dendritic cells. J Immunol (2014) 193:5420-33. doi:10.4049/jimmunol.1303359
21. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol (2002) 76:12388-93. doi:10.1128/JVI.76.23.12388-12393.2002
22. Umeshappa CS, Nanjundappa RH, Xie Y, Freywald A, Xu Q, Xiang J. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency. Immunology (2013) 138:298-306. doi:10.1111/imm.12033
23. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol (2006) 177:2888-98. doi:10.4049/jimmunol.177.5.2888
24. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 18:274-80. doi:10.1038/nm.2612
25. Tripp RA, Tompkins SM. Virus-vectored influenza virus vaccines. Viruses (2014) 6:3055-79. doi:10.3390/v6083055
26. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 80:11756-66. doi:10.1128/jvi.01460-06
27. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 204:845-53. doi:10.1093/infdis/jir436
28. Guo H, Baker SF, Martinez-Sobrido L, Topham DJ. Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus. J Virol (2014) 88:12006-16. doi:10.1128/JVI.01847-14
29. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, Kok T, et al. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J Virol (2010) 84:4212-21. doi:10.1128/jvi.02508-09
30. Pedersen GK, Sjursen H, Nostbakken JK, Jul-Larsen A, Hoschler K, Cox RJ. Matrix M adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4 T cell responses in man. Hum Vaccin Immunother (2014) 10:2408-16. doi:10.4161/hv.29583
31. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol (2012) 32:595-603. doi:10.1007/s10875-011-9632-5
32. Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine (2014) 32:5816-23. doi:10.1016/j.vaccine.2014.08.031
33. Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol (2013) 91:96-104. doi:10.1038/icb.2012.54
34. Cobbin JC, Zeng W, Jackson DC, Brown LE. Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza. PLoS One (2014) 9:e115356. doi:10.1371/journal.pone.0115356
35. Ichihashi T, Satoh T, Sugimoto C, Kajino K. Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T cell responses. PLoS One (2013) 8:e60068. doi:10.1371/journal.pone.0060068
36. Matsui M, Kohyama S, Suda T, Yokoyama S, Mori M, Kobayashi A, et al. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun (2010) 391:1494-9. doi:10.1016/j.bbrc.2009.12.100
37. Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One (2011) 6:e24626. doi:10.1371/journal.pone.0024626
38. Soema PC, Rosendahl Huber SK, Willems GJ, Jiskoot W, Kersten GF, Amorij JP. Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine. Pharm Res (2015) 32:1505-15. doi:10.1007/s11095-014-1556-3
39. Francis JN, Bunce CJ, Horlock C, Watson JM, Warrington SJ, Georges B, et al. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine (2015) 33:396-402. doi:10.1016/j.vaccine.2014.06.006
40. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine (2012) 30:4655-60. doi:10.1016/j.vaccine.2012.04.089
41. Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J Nanobiotechnology (2013) 11:10. doi:10.1186/1477-3155-11-10
42. Szurgot I, Szolajska E, Laurin D, Lambrecht B, Chaperot L, Schoehn G, et al. Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform. Vaccine (2013) 31:4338-46. doi:10.1016/j.vaccine.2013.07.021
43. Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, et al. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J Virol (2013) 87:5985-93. doi:10.1128/jvi.00120-13
44. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One (2012) 7:e48322. doi:10.1371/journal.pone.0048322
45. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis (2012) 55:19-25. doi:10.1093/cid/cis327
46. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One (2013) 8:e62778. doi:10.1371/journal.pone.0062778
47. Wei H, Lenz SD, Thompson DH, Pogranichniy RM. DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N1. Viral Immunol (2014) 27:14-9. doi:10.1089/vim.2013.0080
48. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs (2011) 71:1591-622. doi:10.2165/11206860-000000000-00000
49. Boesteanu AC, Babu NS, Wheatley M, Papazoglou ES, Katsikis PD. Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus. Vaccine (2010) 29:314-22. doi:10.1016/j.vaccine.2010.10.036
50. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig (1998) 15:1-12. doi:10.2165/00044011-199815010-00001
51. Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol (2012) 90:571-8. doi:10.1038/icb.2011.70
52. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol (2012) 19:979-90. doi:10.1128/cvi.00016-12
53. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One (2012) 7:e30898. doi:10.1371/journal.pone.0030898
54. Budimir N, De Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, et al. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir Viruses (2013) 7:1202-9. doi:10.1111/irv.12142
55. Budimir N, De Haan A, Meijerhof T, Waijer S, Boon L, Gostick E, et al. Critical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine. PLoS One (2013) 8:e63163. doi:10.1371/journal.pone.0063163
56. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 21:3212-8. doi:10.1016/S0264-410X(03)00234-2
57. Hong DK, Chang S, Botham CM, Giffon TD, Fairman J, Lewis DB. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol (2010) 84:12691-702. doi:10.1128/JVI.00769-10
58. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine (2008) 26:2350-9. doi:10.1016/j.vaccine.2008.02.063
59. De Vries JJ, Bungener L, Ter Veer W, Van Alphen L, Van Der Ley P, Wilschut J, et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine (2009) 27:947-55. doi:10.1016/j.vaccine.2008.11.046
60. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine (2009) 27:7367-76. doi:10.1016/j.vaccine.2009.09.044
61. Radosevic K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine (2008) 26:3640-6. doi:10.1016/j.vaccine.2008.04.071
62. Rosendahl Huber S, Van Beek J, De Jonge J, Luytjes W, Van Baarle D. T cell responses to viral infections-opportunities for peptide vaccination. Front Immunol (2014) 5:171. doi:10.3389/fimmu.2014.00171
63. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol (2007) 179:2187-94. doi:10.4049/jimmunol.179.4.2187
64. Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine (2002) 20:3123-9. doi:10.1016/S0264-410X(02)00261-X
65. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine (2000) 18:1327-33. doi:10.1016/S0264-410X(99)00404-1
66. Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol (2007) 37:2441-9. doi:10.1002/eji.200737254
67. Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol (2013) 91:184-94. doi:10.1038/icb.2012.78
68. De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, et al. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum Vaccin Immunother (2014) 10:256-62. doi:10.4161/hv.28135
69. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther (2014) 22:233-8. doi:10.1038/mt.2013.162
70. Slutter B, Pewe LL, Lauer P, Harty JT. Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine. J Immunol (2013) 190:3854-8. doi:10.4049/jimmunol.1202790
71. Luo J, Zheng D, Zhang W, Fang F, Wang H, Sun Y, et al. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol J (2012) 9:286. doi:10.1186/1743-422X-9-286
72. Valkenburg SA, Venturi V, Dang TH, Bird NL, Doherty PC, Turner SJ, et al. Early priming minimizes the age-related immune compromise of CD8(+) T cell diversity and function. PLoS Pathog (2012) 8:e1002544. doi:10.1371/journal.ppat.1002544
73. Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slutter B, et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release (2012) 161:363-76. doi:10.1016/j.jconrel.2011.12.039
74. Wu T, Hu Y, Lee Y-T, Bouchard KR, Benechet A, Khanna K, et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol (2014) 95:215-24. doi:10.1189/jlb.0313180
75. Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y, et al. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity (2014) 41:633-45. doi:10.1016/j.immuni.2014.09.007
76. Shane HL, Klonowski KD. Every breath you take: the impact of environment on resident memory CD8 T cells in the lung. Front Immunol (2014) 5:320. doi:10.3389/fimmu.2014.00320
77. Wakim LM, Smith J, Caminschi I, Lahoud MH, Villadangos JA. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. Mucosal Immunol (2015). doi:10.1038/mi.2014.133
78. Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity (2013) 39:939-48. doi:10.1016/j.immuni.2013.09.013
79. Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis (2010) 10:699-711. doi:10.1016/s1473-3099(10)70157-2
80. Tonnis WF, Kersten GF, Frijlink HW, Hinrichs WL, De Boer AH, Amorij JP. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv (2012) 25:249-60. doi:10.1089/jamp.2011.0931
81. Van Els C, Mjaaland S, Naess L, Sarkadi J, Gonczol E, Korsholm KS, et al. Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother (2014) 10:1935-48. doi:10.4161/hv.28639
82. Hillaire ML, Rimmelzwaan GF, Kreijtz JH. Clearance of influenza virus infections by T cells: risk of collateral damage? Curr Opin Virol (2013) 3:430-7. doi:10.1016/j.coviro.2013.05.002
83. Kim JE, Bauer S, La KS, Lee KH, Choung JT, Roh KH, et al. CD4+/CD8+ T lymphocytes imbalance in children with severe 2009 pandemic influenza A (H1N1) pneumonia. Korean J Pediatr (2011) 54:207-11. doi:10.3345/kjp.2011.54.5.207
84. McNally B, Ye F, Willette M, Flano E. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J Virol (2013) 87:12916-24. doi:10.1128/jvi.02423-13
85. Rutigliano JA, Sharma S, Morris MY, Oguin TH III, McClaren JL, Doherty PC, et al. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J Virol (2014) 88:1636-51. doi:10.1128/jvi.02851-13
86. Moise L, Liu R, Gutierrez A, Tassone R, Bailey-Kellogg C, Martin B, et al. Immune camouflage: relevance to vaccine design and human immunology. Hum Vaccin Immunother (2014) 10(12):3570-5. doi:10.4161/hv.36134
87. Keskin DB, Reinhold BB, Zhang GL, Ivanov AR, Karger BL, Reinherz EL. Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity. Proc Natl Acad Sci U S A (2015) 112(7):2151-6. doi:10.1073/pnas.1423482112